Breaking News Instant updates and real-time market news.

REGN

Regeneron

$447.15

-5.82 (-1.28%)

, MRK

Merck

09:15
10/13/17
10/13
09:15
10/13/17
09:15

Barclays cautious on Merck and Regeneron into Q3 results

In a research note previewing the Q3 earnings reports for U.S. Biopharmaceuticals, Barclays analyst Geoff Meacham says he's positive on positive on Amgen (AMGN) and Alexion Pharmaceuticals (ALXN), cautious on Merck (MRK), and bearish on Regeneron (REGN). The analyst made a host of price target changes, including raising Amgen's target to $190 from $180, AbbVie's (ABBV) target to $90 from $68 and Bristol-Myers' target to $65 from $58.

REGN

Regeneron

$447.15

-5.82 (-1.28%)

MRK

Merck

AMGN

Amgen

$182.76

-1.39 (-0.75%)

ALXN

Alexion

$141.46

0.23 (0.16%)

ABBV

AbbVie

BMY

Bristol-Myers

  • 15

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 23

    Oct

  • 23

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 27

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 09

    Nov

  • 30

    Nov

  • 02

    Dec

  • 02

    Feb

  • 03

    Feb

  • 05

    Mar

  • 30

    Apr

  • 17

    May

  • 28

    May

REGN Regeneron
$447.15

-5.82 (-1.28%)

10/11/17
BARD
10/11/17
NO CHANGE
Target $69
BARD
Outperform
AnaptysBio price target raised to $69 from $36 at Baird
Baird analyst Neena Bitritto-Garg raised her price target on AnaptysBio (ANAB) to $69 from $36 following positive proof-of-concept data for its anti-IL-33 antibody, adding that its scores look more impressive than Sanofi (SNY) and Regeneron's (REGN) initial data for atopic dermatitis for Dupixent. The analyst raised her price target to reflect the strong validation of its mechanism and Bitritto-Garg reiterated her Outperform rating on AnaptysBio shares.
10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
Overweight
Regeneron, Sanofi overhang removed by court ruling, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that the U.S. Court of Appeals ruled in favor of Regeneron (REGN) and Sanofi (SNY) and vacated an injunction granted to Amgen (AMGN) to compel its competitors to pull Praluent from the market. While "this battle is far from over" and Raymond expects a new trial will be the next step, he also believes the ruling remove a significant marketing overhang that had hamstrung Regeneron and Sanofi sales reps. The analyst keeps an Overweight rating on Regeneron shares, which are currently halted with news pending.
09/29/17
09/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Regeneron (REGN) assumed with an Overweight at Piper Jaffray. 2. MasterCard (MA) and Visa (V) were initiated with an Overweight at Cantor Fitzgerald. 3. Liberty Global (LBTYA, LBTYK) and Liberty Global LiLAC (LILA) were initiated with a Buy at Buckingham. 4. Corbus Pharmaceuticals (CRBP) coverage assumed with a Buy at Noble Financial. 5. Medpace (MEDP) initiated with a Market Perform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/17
PIPR
09/28/17
INITIATION
Target $540
PIPR
Overweight
Regeneron assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond assumed coverage of Regeneron with an Overweight rating and $540 price target. The firm previously had an Overweight rating and $557 price target on the stock.
MRK Merck

08/23/17
RAJA
08/23/17
NO CHANGE
Target $36
RAJA
Strong Buy
Paratek takeover speculation 'seems plausible,' says Raymond James
After Bloomberg reported that Paratek Pharmaceuticals (PRTK) is exploring its strategic options, including a possible sale, after receiving takeover interest, Raymond James analyst Laura Chico said she sees omadacycline as a promising asset and sees a takeout as "certainly one plausible outcome." While its "probably premature to think about a takeout price," Chico said that a possible price could arguably fall in the high-$40 to low-$50 range, adding that Merck (MRK), Pfizer (PFE) and Allergan (AGN) would all be potential buyers. She keeps a Strong Buy rating and $36 price target on Paratek shares.
09/11/17
STFL
09/11/17
NO CHANGE
Target $29
STFL
Buy
NewLink Genetics price target raised to $29 from $14 at Stifel
Stifel analyst Stephen Willey believes recently-updated melanoma data from both NewLink Genetics' (NLNK) phase 2 indoximod program and Incyte (INCY) and Merck's (MRK) ESMO presentation confirm IDO inhibitors are more-than-likely synergizing with PD-1 inhibition, adding that NewLink's drug appears to yield "slightly-better efficacy" in "slightly-healthier" patients. He increased his price target on NewLink to $29 from $14 to reflect favorable risk adjustments and higher melanoma sales estimates and keeps a Buy rating on the stock.
09/11/17
BMOC
09/11/17
NO CHANGE
BMOC
Incyte trial result 'assures commercial success,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says the results of a trial of Incyte's (INCY) epacadostat, its selective IDO1 enzyme inhibitor, in combination with Merck's (MRK) Keytruda, in patients with advanced melanoma eliminates the risk of an upcoming Phase 3 trial of epacadostat and "assures its commercial success." The analyst adds, however, that "the bar continues to be raised for IO combinations," which may make it difficult for Incyte's stock to rise in the near-term. The analyst trimmed his price target on the shares to $163 from $172 to reflect the company's capital raise. But he keeps an Outperform rating on the stock.
09/18/17
JEFF
09/18/17
NO CHANGE
JEFF
AbbVie remains top global Pharma pick at Jefferies
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals, followed by Bayer (BAYRY). In the U.S., the analyst lists Zoetis (ZTS), Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) as his top picks behind AbbVie. Merck (MRK) and Novo Nordisk (NVO) are the analyst's least preferred stocks. Holford cut his price target for Underperform-rated Merck to $52 from $55 and raised his price target for Buy-rated Zoetis to $77 from $74.
AMGN Amgen
$182.76

-1.39 (-0.75%)

10/04/17
NOMU
10/04/17
NO CHANGE
Target $44
NOMU
Buy
CytomX price target raised to $44 from $32 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for CytomX Therapeutics (CTMX) to $44 after the company announced yesterday strategic collaboration with Amgen (AMGN) to co-develop an EGFRxCD3 Probody. The new price target incorporates potential royalties of $1.1B on sales of EGFRxCD3. The analyst keeps a Buy rating on CytomX.
10/05/17
BOFA
10/05/17
NO CHANGE
BOFA
Buy
Amgen price target raised to $210 at BofA/Merrill
BofA/Merrill analyst Ying Huang raised Amgen's price target to $210 to reflect the potential impact of proposed tax reform and benefits from a potential repatriation of profits. Huang rates Amgen a Buy.
10/04/17
WEDB
10/04/17
NO CHANGE
Target $37
WEDB
Outperform
CytomX Therapeutics price target raised to $37 from $26 at Wedbush
Wedbush analyst Robert Driscoll raised his price target for CytomX Therapeutics (CTMX) to $37 from $26 to reflect his increased confidence in its platform, and the extended cash runway, which the company believes to be sufficient to at least 2020. The analyst notes that the company has added Amgen (AMGN) to the Partner List with Bispecific Collaboration. He reiterates an Outperform rating on CytomX Therapeutics' shares.
ALXN Alexion
$141.46

0.23 (0.16%)

09/25/17
LEER
09/25/17
NO CHANGE
Target $182
LEER
Outperform
Alexion Soliris to continue dominance through 2020, says Leerink
Leerink analyst Geoffrey Porges notes that Alexion's Soliris was the first complement inhibitor to be approved by the FDA or EMA and has remained the only terminal complement inhibitor on the market. While some competitors have advanced to pivotal trials, and have established safety and efficacy, none have shown themselves to be superior to Soliris in efficacy, nor more convenient than ALXN1210, he adds. The analyst believes the development timelines for these new entrants suggest that Soliris will continue its dominance of the category through 2020, and even then will face its biggest challenge from Alexion's own next generation complement inhibitor, ALXN1210. Porges reiterates an Outperform rating and $182 price target on the shares.
09/13/17
LEER
09/13/17
NO CHANGE
Target $182
LEER
Outperform
Alexion price target raised to $182 from $170 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Alexion to $182 from $170 on valuation. The analyst reiterates an Outperform rating on the shares.
09/14/17
LEER
09/14/17
NO CHANGE
Target $182
LEER
Outperform
Long-term follow-up confirms Alexion Soliris benefit, says Leerink
Leerink analyst Geoffrey Porges notes that Alexion announced the presentation of additional results from the open-label extension of the pivotal phase III REGAIN study of Soliris in refractory generalized myasthenia gravis. The analyst believes this longer-term follow-up analysis is highly supportive of the upcoming PDUFA on October 23. Porges reiterates an Outperform rating and $182 price target on the shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $161
RBCM
Outperform
Alexion initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Alexion with an Outperform and a $161 price target saying shares are undervalued following management changes and restructuring. He said Soliris market dynamics suggest continued future growth despite PNH Patient competition.
ABBV AbbVie

10/11/17
10/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying J&J's Pharma division is "under-modeled" by analysts and will drive above-consensus revenue and earnings growth. 2. Visa (V) and MasterCard (MA) were upgraded to Outperform from Market Perform at Wells Fargo. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying the recent three consecutive quarters of weak results is an "anomaly" given the company's long term track record of consistent mid-single-digit or higher organic growth. 4. AbbVie (ABBV) upgraded to Outperform from Market Perform at Cowen with analyst Steve Scala saying AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week. 5. PayPal (PYPL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst James Faucette calling it among the few large companies that can deliver high-teens revenue and 20% EPS growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/17
WBLR
10/09/17
NO CHANGE
Target $110
WBLR
Outperform
AbbVie fair value estimate raised to $110 from $76 at William Blair
William Blair analyst Y. Katherine Xu raised her fair value estimate for AbbVie to $110 to reflect progress with the pipeline and the recent Humira patent victory. The analyst now models Humira to maintain U.S. patent exclusivity through the end of 2022, extended from her previous estimate of 2020. Xu believes pivotal data readouts through year-end 2017 will continue to support the outperformance of AbbVie shares. She keeps an Outperform rating on the name.
10/09/17
LEER
10/09/17
NO CHANGE
LEER
Leerink not worried about JAK safety, AbbVie '494 profile so far 'ok'
Leerink analyst Geoffrey Porges notes that the delayed approval of Incyte (INCY)/Eli Lilly (LLY) baricitinib and the reported thromboembolic events in AbbVie's (ABBV) ABT494/upadacitinib trials have called into question the safety of oral Janus kinase, or JAK, inhibitors. The analyst says that his detailed review of the safety literature suggests that these medicines offer an acceptable risk/benefit profile for serious inflammatory diseases and do not confer a significant increase in cardiovascular risk or venous thromboembolic events. Further, Porges continues to believe AbbVie's upadacitinib and Gilead's (GILD) filgotinib will be approved for serious inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, and will capture the majority share of his peak risk-adjusted $12B estimated JAK market.
10/11/17
COWN
10/11/17
UPGRADE
Target $105
COWN
Outperform
AbbVie upgraded to Outperform from Market Perform at Cowen
Cowen analyst Steve Scala upgraded AbbVie to Outperform and raised his price target for the shares to $105 from $95. AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week, Scala tells investors in a research note. He increased his out-year estimates for AbbVie after several of its drugs were highlighted during the conference. The stock is attractively valued versus the group overall, Scala argues.
BMY Bristol-Myers

09/15/17
JEFF
09/15/17
NO CHANGE
Target $72
JEFF
Buy
Bristol-Myers price target raised to $72 from $66 at Jefferies
Jefferies analyst Jeffrey Holford raised his price target for Bristol-Myers Squibb to $72 saying new opportunities for the Opdivo/Yervoy combo offer upside to estimates. The analyst says this, along with higher estimates for Eliquis and "significant" margin expansion over the mid term support his higher price target. Holford keeps a Buy rating on Bristol.
10/06/17
UBSW
10/06/17
NO CHANGE
Target $72
UBSW
Buy
Bristol-Myers price target raised to $72 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Bristol-Myers to $72 from $62 to reflect higher product sales and flat operating expenses. The analyst also increased his sales for Opdivo given the failure of competitive drug trials and new uses for it in the head and neck setting. He believes Bristol-Myers remains the best positioned in immuno-oncology and at current prices offers a favorable risk/reward. Goodman reiterated his Buy rating on Bristol-Myers shares.
09/15/17
DBAB
09/15/17
NO CHANGE
Target $20
DBAB
Buy
Halozyme price target raised to $20 from $17 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme (HALO) to $20 saying he's bullish following the new Enhanze partnership. Yesterday's dual announcements for additional Enhanze collaborations are "clear positives" for the stock, Peters tells investors in a research note. He says the size of the Bristol-Myers Squibb deal, including the upfront payment, is larger than expected. The analyst reiterates a Buy rating on Halozyme.

TODAY'S FREE FLY STORIES

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

, HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

20:25
02/21/18
02/21
20:25
02/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

APA

Apache

$37.20

-1.1 (-2.87%)

LDOS

Leidos

$65.21

-1.02 (-1.54%)

W

Wayfair

$95.69

-0.61 (-0.63%)

OA

Orbital ATK

$131.80

-0.02 (-0.02%)

TREE

LendingTree

$371.25

-7.8 (-2.06%)

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

TPX

Tempur Sealy

$54.97

1.17 (2.17%)

SAFM

Sanderson Farms

$128.00

-3.44 (-2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 08

    Mar

  • 20

    Mar

  • 29

    Mar

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

20:04
02/21/18
02/21
20:04
02/21/18
20:04
Syndicate
Aimmune 5.5M share Secondary priced at $32.00 »

BofA/Merrill, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 11

    Mar

  • 22

    Feb

20:00
02/21/18
02/21
20:00
02/21/18
20:00
General news
Breaking General news story  »

Minneapolis Federal…

NUAN

Nuance

$16.28

-0.28 (-1.69%)

19:10
02/21/18
02/21
19:10
02/21/18
19:10
Periodicals
Nuance discontinues Swype feature development, Verge reports »

Nuance has ceased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SSNLF

Samsung

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

19:04
02/21/18
02/21
19:04
02/21/18
19:04
Hot Stocks
Samsung, Qualcomm expand foundry cooperation on EUV process technology »

Samsung Electronics…

SSNLF

Samsung

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

CATY

Cathay General

$42.84

0.43 (1.01%)

18:59
02/21/18
02/21
18:59
02/21/18
18:59
Hot Stocks
Cathay General executive chairman Cheng sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$30.00

-0.08 (-0.27%)

18:42
02/21/18
02/21
18:42
02/21/18
18:42
Earnings
Sunoco reports Q4 EPS $2.01, may not compare to consensus 35c »

Reports Q4 revenue $3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

USFD

US Foods

$32.29

0.33 (1.03%)

18:39
02/21/18
02/21
18:39
02/21/18
18:39
Hot Stocks
US Foods director Lederer sells 98,702 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:38
02/21/18
02/21
18:38
02/21/18
18:38
Earnings
Volaris reports Q4 28c, consensus 20c »

Reports Q4 revenue $336M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:34
02/21/18
02/21
18:34
02/21/18
18:34
Earnings
Breaking Earnings news story on Volaris »

Volaris reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:29
02/21/18
02/21
18:29
02/21/18
18:29
Earnings
Valmont sees 2018 adjusted $8.00, consensus $8.15 »

Sees 2018 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:27
02/21/18
02/21
18:27
02/21/18
18:27
Earnings
Valmont reports Q4 adjusted EPS $1.67, consensus $1.69 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

CTRV

ContraVir Pharmaceuticals

$0.25

-0.013 (-5.00%)

18:11
02/21/18
02/21
18:11
02/21/18
18:11
Hot Stocks
ContraVir Pharmaceuticals' hepatitis B treatment receives FDA Orphan designation »

ContraVir…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:06
02/21/18
02/21
18:06
02/21/18
18:06
Earnings
AAC Holdings sees FY18 adjusted EPS 70c-75c, consensus 53c »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:05
02/21/18
02/21
18:05
02/21/18
18:05
Earnings
AAC Holdings reports Q4 adjusted EPS 10c, consensus 4c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DNKN

Dunkin' Brands

$60.70

-1.45 (-2.33%)

18:04
02/21/18
02/21
18:04
02/21/18
18:04
Hot Stocks
Baskin-Robbins expands in Toronto with plans for four new locations »

Baskin-Robbins, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$102.43

0.05 (0.05%)

18:01
02/21/18
02/21
18:01
02/21/18
18:01
Hot Stocks
Celanese to increase price of acetyl intermediate products »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 30

    May

TUSK

Mammoth Energy

$20.04

-0.11 (-0.55%)

17:56
02/21/18
02/21
17:56
02/21/18
17:56
Earnings
Mammoth Energy reports Q4 EPS $1.48, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

NSPR

InspireMD

$4.20

-0.26 (-5.83%)

17:53
02/21/18
02/21
17:53
02/21/18
17:53
Syndicate
Breaking Syndicate news story on InspireMD »

InspireMD files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETFC

E-Trade

$51.76

-0.25 (-0.48%)

17:52
02/21/18
02/21
17:52
02/21/18
17:52
Syndicate
Breaking Syndicate news story on E-Trade »

E-Trade files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$39.91

1.01 (2.60%)

17:47
02/21/18
02/21
17:47
02/21/18
17:47
Syndicate
Breaking Syndicate news story on Spirit Airlines »

Spirit Airlines files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAND

Bandwidth

$24.09

0.18 (0.75%)

, CAR

Avis Budget

$38.96

-0.98 (-2.45%)

17:42
02/21/18
02/21
17:42
02/21/18
17:42
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

BAND

Bandwidth

$24.09

0.18 (0.75%)

CAR

Avis Budget

$38.96

-0.98 (-2.45%)

MB

Mindbody

$33.35

-0.1 (-0.30%)

SAIL

SailPoint Technologies

$17.92

0.47 (2.69%)

STMP

Stamps.com

$184.95

-5.1 (-2.68%)

GPOR

Gulfport Energy

$8.41

-0.32 (-3.67%)

SNPS

Synopsys

$88.46

-1.3 (-1.45%)

PE

Parsley Energy

$23.10

-0.19 (-0.82%)

P

Pandora

$4.87

-0.46 (-8.63%)

MLNX

Mellanox

ROKU

Roku

$51.10

-0.08 (-0.16%)

AAOI

Applied Optoelectronics

$34.55

1.22 (3.66%)

SRCL

Stericycle

$74.91

-0.31 (-0.41%)

CSLT

Castlight Health

$3.85

0.3 (8.45%)

UCTT

Ultra Clean

$19.96

-0.4 (-1.96%)

TRN

Trinity Industries

$35.23

0.47 (1.35%)

RGR

Sturm, Ruger

$47.30

-1.05 (-2.17%)

CONE

CyrusOne

$48.81

-1.56 (-3.10%)

ADXS

Advaxis

$2.51

-0.08 (-3.09%)

GWPH

GW Pharmaceuticals

$132.33

1.5 (1.15%)

OMF

OneMain Holdings

$31.67

-0.22 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 11

    Mar

  • 13

    Mar

  • 14

    Mar

  • 21

    Mar

  • 26

    Mar

  • 28

    Mar

  • 29

    Mar

  • 03

    Apr

  • 15

    May

  • 23

    May

  • 27

    Jun

  • 22

    Feb

CLI

Mack-Cali Realty

$18.33

-0.25 (-1.35%)

17:40
02/21/18
02/21
17:40
02/21/18
17:40
Earnings
Breaking Earnings news story on Mack-Cali Realty »

Mack-Cali Realty sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLI

Mack-Cali Realty

$18.33

-0.25 (-1.35%)

17:39
02/21/18
02/21
17:39
02/21/18
17:39
Earnings
Breaking Earnings news story on Mack-Cali Realty »

Mack-Cali Realty reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$63.62

-0.75 (-1.17%)

17:32
02/21/18
02/21
17:32
02/21/18
17:32
Hot Stocks
Macquarie Infrastructure to reduce 2018 dividend to help fund asset repurposing »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.